ISAR-DESIRE 4 Is First Trial to Examine Role of Lesion Preparation before Drug-Coated Balloon Therapy in Restenosis

BIOTRONIK's Pantera Lux Drug-Coated Balloon Convinces in Highly Complex Population

SAN FRANCISCO, US and BUELACH, Switzerland, October 15, 2015 – BIOTRONIK, a leading manufacturer of cardio- and endovascular medical devices, announced today that the results from the ISAR-DESIRE 4 study were presented at TCT 2015. The trial examined a patient population with in-stent restenosis following limus-eluting stent implantation—indicative of a severe disease state, as the current gold standard of therapy has failed for these patients. Investigators sought to determine whether treatment of in-stent restenosis is more effective when the lesion is prepared by means of scoring balloon (SCB) prior to drug-coated balloon (DCB) therapy with Pantera Lux.

“In-stent restenosis is the main indication for DCB, and represents an especially challenging population. Though previous trials have shown very positive outcomes for DCB in treating in-stent restenosis1, little was known as to whether lesion preparation would have any influence on the outcome,” commented clinical investigator Dr. Robert Byrne, German Heart Center, Munich, Germany. “ISAR- DESIRE 4 further establishes DCB as a valuable tool to treat in-stent restenosis, independent of the type of
lesion preparation.”

ISAR-DESIRE 4 randomized 250 patients into two study arms; after lesion preparation with either standard uncoated balloon predilatation or SCB, both groups were treated with Pantera Lux. The primary endpoint was percent diameter stenosis (%DS) at six to eight months. Though primary endpoint outcomes for the SCB group were slightly improved (35%DS v. 40%DS, p=0.047), DCB treatment with Pantera Lux effected overall positive clinical outcomes for both.

“In the most challenging cases seen in this trial, it appears that Pantera Lux’s performance can be even further enhanced by using SCB predilatation,” stated Dr. Byrne. “These benefits are likely caused by better drug uptake due to micro-injuries created by the scoring balloon.”

“Pantera Lux has established itself in both clinical trials23 and routine clinical practice as a highly safe and efficacious treatment for in-stent restenosis, regardless of whether the lesion is first prepared with a scoring balloon,” commented Dr. Alexander Uhl, Vice President Marketing, BIOTRONIK Vascular Intervention. “These results offer further confirmation that DCB is the current gold standard for treating in-stent restenosis without leaving another implant behind.”

  1. Byrne RA, et al. Lancet. 2013, 381(9865)
  2. Toelg R, et al. EuroIntervention. 2014, 10(5)
  3. Hehrlein C, et al. Cardiovasc Revasc Med. 2012, 13(5)


At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.